Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026

Phase 3Treprostinil Palmitil Inhalation PowderPositive

AI Analysis

Summary

Insmed is presenting its global Phase 3 PALM clinical program evaluating treprostinil palmitil inhalation powder across four pivotal studies targeting progressive pulmonary diseases at the CHEST 2026 conference.

Clinical Trial Data

Phase

Importance:5/10

Sentiment:

0.30

Phase 3Pulmonary diseasePAHILDIPFConference presentationMultiple indications

Related Companies

$GBCMD $ACTI.ST

Read the original article

Published by PR Newswire Biotech on October 15, 2026 11:00 AM

Read Original